Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRK-439 in healthy adults
NCT07444294Phase 1Recruiting
- Sponsor
- Scholar Rock
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SRK-439 in obesity (2 arms), sponsored by Scholar Rock. Primary endpoint: Safety and Tolerability of SRK-439 at 32 weeks. Started Nov 2025; status: recruiting.
02
Drugs
SRK-439
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07444294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444294.